Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-Mutated population with advanced non-small-cell lung cancer

被引：0
|
作者：
Chouaid, Christos
De Pouvourville, Gerard
Laura, Luciani
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.PA2794
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA2794
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-mutated population with advanced non-small-cell lung cancer.
    Chouaid, Christos
    Luciani, Laura
    Le Lay, Kate
    De Pouvourville, Gerard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS GEFITINIB IN EGFR-MUTATED POPULATION WITH ADVANCED NON-SMALL-CELL LUNG CANCER IN FRANCE
    de Pouvourville, G.
    Luciani, L.
    Le Lay, K.
    Po, P.
    Bennouna, J.
    Perol, M.
    Moro-Sibilot, D.
    Vergnengre, A.
    Chouaid, C.
    VALUE IN HEALTH, 2017, 20 (09) : A439 - A439
  • [3] Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer
    Wang, Hao
    Zeng, Chenxin
    Li, Xin
    Wang, Youjie
    Li, Xinyi
    Ge, Weihong
    FUTURE ONCOLOGY, 2019, 15 (02) : 181 - 191
  • [4] Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers
    Chouaid, Christos
    Luciani, Laura
    Lelay, Katell
    Do, Pascal
    Bennouna, Jaafar
    Perol, Maurice
    Moro-Sibilot, Denis
    Vergnenegre, Alain
    de Pouvourville, Gerard
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (10) : 1496 - 1502
  • [5] Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Alos-Alminana, Manuel
    Cortijo, Julio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (11) : 853 - 863
  • [6] Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Cortijo, Julio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (04) : 325 - 335
  • [7] Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer
    Wang, Debby D.
    Lee, Victor H. F.
    Zhu, Guangyu
    Zou, Bin
    Ma, Lichun
    Yan, Hong
    MOLECULAR BIOSYSTEMS, 2016, 12 (05) : 1552 - 1563
  • [8] Cost-Effectiveness Analysis of Different Sequences of Osimertinib Administration for EGFR-Mutated Non-Small-Cell Lung Cancer
    Li, W.
    Qian, L.
    Li, W.
    Chen, X.
    He, H.
    Tian, H.
    Zhao, Y.
    Wang, X.
    Cui, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1067 - S1067
  • [9] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
    Aguilar-Serra, J.
    Gimeno-Ballester, V
    Pastor-Clerigues, A.
    Milara, J.
    Trigo-Vicente, C.
    Cortijo, J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 637 - 646
  • [10] EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis
    You, Joyce H. S.
    Cho, William C. S.
    Ming, Wai-Kit
    Li, Yu-Chung
    Kwan, Chung-Kong
    Au, Kwok-Hung
    Au, Joseph Siu-Kie
    PLOS ONE, 2021, 16 (03):
12345